Login
$OBIO
$7.12 +$0.00 (0.0%) After hours

$OBIO 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Orchestra BioMed Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 15,000,000 shares (the “Firm Shares”) of Common Stock, ...

01 Oct 2026 8-K: Regulation FD Disclosure; Other Events

330 patients randomized as of September 30, 2026, surpassing full trial enrollment target

08 Sep 2026 8-K: Regulation FD Disclosure

Accelerating high - impact technologies to patients through risk - reward sharing partnerships Corporate Overview | September 2026 Nasdaq : OBIO

23 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 23, 2026, Orchestra BioMed Holdings, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 59,880,715 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock...

13 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

On February 12, 2026, the Board of Directors (the “Board”) of Orchestra BioMed Holdings, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), approved the 2026 cash bonu...

12 Jan 2026 8-K: Other Events

$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts

13 Nov 2025 8-K: Regulation FD Disclosure

David Hochman, Chairman, Chief Executive Officer and Founder

30 Oct 2025 8-K: Regulation FD Disclosure

Orchestra BioMed Corporate Overview October 2025 Nasdaq: OBIO

28 Oct 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more

This STOCK PURCHASE AGREEMENT (this “Agreement”) is dated as of October 24, 2025, by and between Orchestra BioMed Holdings, Inc., a Delaware corporation (the “Issuer”), and Terumo Medical Corporation, a Delaware corporation (the “Investo...

04 Aug 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

Orchestra BioMed Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) (i) an aggregate of 9,413,637 shares (the “Firm Shares”) of Common Stoc...

31 Jul 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +3 more

*** Certain information in this document has been excluded pursuant to Regulation S-K, item 601(b)(10). Such excluded information is not material and is information that the company treats as private or confidential. Such omitted informa...

24 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 24, 2025, Orchestra BioMed Holdings, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 38,312,512 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock...

29 Apr 2025 8-K: Regulation FD Disclosure; Other Events

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

03 Mar 2025 8-K: Regulation FD Disclosure

ͮŽƌƉŽƌĂƚĞWƌĞƐĞŶƚĂƚŝŽŶY ϭϮϬϮϱ Ϯ Forward - Looking Statements This presentation has been prepared for informational purposes only from information supplied by Orchestra BioMed Holdings, Inc . , referred to herein as “we,” “our,” “Orc...

25 Feb 2025 8-K: Departure/Election of Directors or Officers; Compensation

Policy With Respect to the Payment of Taxes Upon Vesting of Restricted Stock Units for Section 16 Officers

05 Feb 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

12 Aug 2024 8-K: Other Events

Orchestra BioMed Holdings, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through TD Securities (USA) LLC, as sales agent and/or principal (t...

30 Jul 2024 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

John Mack brings over 30 years of diverse medical device and healthcare technology experience to the Orchestra BioMed Board of Directors

20 Jun 2024 8-K: Submission of Matters to a Vote of Security Holders

On June 20, 2024, Orchestra BioMed Holdings, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 35,786,497 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock...

11 Jun 2024 8-K: Regulation FD Disclosure

Bringing medical inn vation to life Orchestra BioMed AVIM Therapy R&D DAY June 11, 2024

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support